Haematology - National Immunoglobulin Database
Short Description
Download Haematology - National Immunoglobulin Database...
Description
Haematology Jennie Wimperis Consultant Haematologist Norfolk and Norwich University Hospital
Norwich
Immunoglobulin use in haematology 2010 database report
Total Grams Infused for Haematology in 2010 Alloimmune thrombocytopenia fetal therapy (treatment to the mother) 5%
Haemophagocytic lymphohistiocytosis 1%
Other specified uses 4%
Autoimmune haemolytic anaemia 4%
Unspecified use 16%
ITP 70%
Total Grams Infused for Haematology Q1 2010
Alloimmune thrombocytopenia fetal therapy (treatment to the mother) 5% Autoimmune haemolytic anaemia 5%
Haemophagocytic lymphohistiocytosis 1%
Other specified uses 2%
Unspecified use 18%
ITP 69%
Total Grams Infused for Haematology Q2 2010 Alloimmune thrombocytopenia - fetal therapy (treatment to the mother) 4% Autoimmune haemolytic anaemia 4%
Other specified uses 4%
Unspecified use 15%
ITP 73%
Total Grams Infused for Haematology Q3 2010 Alloimmune Haemophagocytic thrombocytopenia - fetal lymphohistiocytosis therapy (treatment to the 1% mother) 4% Autoimmune haemolytic anaemia 5%
Autoimmune (acquired) haemophilia 1%
Other specified uses 3%
Unspecified use 14%
ITP 72%
Total Grams Infused for Haematology Q4 2010
Autoimmune haemolytic anaemia 3%
Haemophagocytic lymphohistiocytosis 1%
Other specified uses 7%
Alloimmune thrombocytopenia - fetal therapy (treatment to the mother) 5% Unspecified use 16%
ITP 68%
Current treatment of Immune Thrombocytopenia
• • • •
ITP – Definition and Terminology therapeutic goals treatment - place of IvIg in treatment new treatments ? effect on IvIg use
Current treatment of Immune Thrombocytopenia
• • • •
ITP – Definition and Terminology therapeutic goals treatment - place of IvIg in treatment new treatments ? effect on IvIg use
International Working Group Consensus 2009 Standardisation of terminology for ITP Definition Acquired immune mediated disorder characterised by isolated thrombocytopenia Defined as a platelet count < 100 x 109/L - (versus often used 150) Terminology Primary immune thrombocytopenia (replacing term idiopathic) Secondary immune thrombocytopenia (SLE, drugs etc) Neonatal Allo Iimmune Thrombocytopenia and Post Transfusional Purpura , Heparin Induced Thrombocytopenia retained Rodeghiero et al: Blood 2009, 113, 2386-2393 NAIT neonatal immune thrombocytopenia, PTP post transfusional purpura ,HITT heparin induced thrombocytopenia
Pathophysiology of ITP • Platelets are coated with autoantibody or immune complexes - removed by spleen, liver and elsewhere • First demonstrated by Harrington 1951 – injected serum from ITP patients into non-ITP volunteers – transient fall in platelet counts • Megakaryocytes often increased but may be decreased • Production reduced in 40% Harrington J Lab Clin Med 38, 1–10 (1951)
Presentation of ITP
International Working Group Consensus 2009 Phases of disease • Newly diagnosed (replacing acute) • Persistent • Chronic
Rodeghiero et al: Blood 2009, 113, 2386-2393
International Working Group Consensus 2009 Severity of disease previously correlated with degree of thrombocytopenia Severe ITP ‘clinically relevant bleeding’ irrespective of platelet count Refractory failed splenectomy or relapse thereafter and have severe ITP or a risk of bleeding Rodeghiero et al: Blood 2009, 113, 2386-2393
Clinical course of ITP Childhood
Adult
Spontaneous remission Chronic ITP
83%
2%
15%
43%
Complete recovery Response to splenectomy
89+%
64%
71%
66%
What actually are the risks of ITP? • Disease impact varies from patient to patient from minor symptoms, such as an increased tendency to bruise, anaemia, or mucosal bleeding, to severe, even fatal bleeding events1 • For those with long-standing, severe refractory ITP2 – Cerebral haemorrhage 3% – Haemorrhagic death 4% – Mortality of chronic disease/treatment 5%
1. Mathias S et al. Curr Med Res & Opinion 2009;25:375–383; 2. George JN & Raskob GE. Semin Hematol 1998;35:5–8
Current treatment of Immune Thrombocytopenia
• • • •
ITP – Definition and Terminology therapeutic goals treatment - place of IvIg in treatment new treatments ? effect on IvIg use
International Working Group Consensus 2010 Therapeutic Goals • provide a safe platelet count i.e. one that prevents bleeding rather than to normal levels • treatment should always be tailored to the individual – treatment may be worse than disease • factors which contribute to management decisions include: – – – – – – –
bleeding other medical problems activity and lifestyle tolerance of side effects planned procedure patient preferences/concerns platelet counts
Platelet >20–30x109/L
Platelet >80 x109/L Platelet >50 x109/L Provan D et al. Blood 2010;15:168–186
Treatment of ITP • platelets are coated with autoantibody or immune complexes - immune suppression/immune modulation • removed by spleen, liver and elsewhere - splenectomy • megakaryocytes often increased but may be decreased production reduced in 40% - stimulation of megakaryocytes
Short course – cure or prolonged remission Continuous or repeated administrations
Indications for treatment of ITP
symptomatic
symptomatic on demand – bleeding, trauma, pre procedure
Current treatment of Immune Thrombocytopenia
• • • •
ITP – Definition and Terminology therapeutic goals treatment - place of IvIg in treatment new treatments ? effect on IvIg use
Treatment of ITP with IvIg Newly diagnosed symptomatic ITP Persistent (3-12 months) or Chronic (>12 months) on demand – bleeding/trauma/pre procedure Long term chronic refractory Dose – 400mg/kg x 5 – 1g/kg 2 days
Current treatment of Immune Thrombocytopenia
• • • •
ITP – Definition and Terminology therapeutic goals treatment - place of IvIg in treatment new treatments ? effect on IvIg use
Recommendations overview of medical management options recent treatments1 Clinical situation
Therapy option
First line (initial treatment for newly diagnosed ITP)
Corticosteroids: dexamethasone, methylprednisolone, prednisolone Intravenous immunoglobulin (Anti-D)
Second line*
Azathioprine Cyclosporin A Cyclophosphamide Danazol Dapsone
Treatment for refractory ITP patients (patients failing first- and secondline therapies)
Category A: treatment options with sufficient data Thrombopoietin-receptor agonists** Category B: treatment options with minimal data and considered to have potential for considerable toxicity Campath-1H Combination of first- and second-line therapies Combination chemotherapy Haemopoietic stem cell transplantation
Mycophenolate mofetil Rituximab Splenectomy Thrombopoietin-receptor agonists** Vinca alkaloids
*Treatment options are listed alphabetically and thus do not indicate a oreferred treatment option. **The EU license for splenectomised adults with ITP who are refractory to other treatments or in non-splenectomised patients where surgery is contraindicated 1 New International Consensus Guidelines Provan, Stasi, Newland et al Blood 2010; 115; 168-186.
Rituximab • anti CD20 humanised McAb – B cells • weekly doses – 375 mg/m2 x 4 – fixed dose 100mg x 4
Response to Rituximab in Children and Adults with ITP Total
100%
100%
Initial Response
57%*
56% *
1 Year
38% *
32% †
2 Years
31% †
25% †
5 Years
21% †
25% †
Median response 10.5 months
Children * Derived from published reports † Long-term follow up data acquired in this study Patel VL, et al. ASH 2010 Abstract 72
Adults
Rituximab is associated with an increased risk of adverse events • Black box warning applied to FDA label1 and special warning to EMEA label2 for – risk of infusion reactions – mucocutaneous reactions – increased risk of PML
• Risk of hepatitis B reactivation1 • Risk of severe infections – French AIR registry: 5.0 severe infections/ 100 patients/year3 PML, progressive multifocal leukoencephalopathy 1. Rituxan label information : http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103705s5344lbl.pdf (date accessed: 19 Sep 2011); 2. Rituximab SmPC 2011: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000165/WC500025821.pdf (date accessed: 19 Sep 2011); 3. Gottenberg JE et al. Arthritis Rheum. 2010; 62:2625-32.
Thrombopoietin-receptor agonists Stimulates platelet production by promoting • Proliferation • Survival • Differentiation of megakaryocyte precursors into mature megakaryocytes • Platelet release May prime platelets for activation
Why should exogenous thrombopoietin be effective in ITP?
Adapted from: Nichol JL. Stem Cells. 1998;16(suppl 2): 165–175.
Thrombopoeitin receptor agonists Nonpeptide Mimetics - Eltrombopag (Revolade), AKR 501 Peptide Mimetics - Romiplostim (N-plate), PEG TPOmp
Incidence of Overall Platelet Response Placebo
Romiplostim
100
Overall Platelet Response (%)
88
83
79 80
60
40 14
20
7 0 0
(p < .0001)
(p < .0001)
(p < .0001)
Splenectomized
Non-splenectomized
Total
Kuter et al. Lancet 2008;371:395–403
Median Platelet Count (x109/L)
Median Weekly Platelet Count - Romiplostim 200
Romiplostim Placebo
Splenectomized
150 100 50 0
1
2
3
4
5
6
7
8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Study Week
Median Platelet Count (x109/L)
Placebo* Romiplostim* 200
21 21 21 21 21 21 21 21 21 21 20 20 20 20 20 20 20 20 18 19 18 18 19 17 19 42 42 42 42 42 42 41 42 41 41 40 39 41 39 40 40 39 40 39 39 40 38 38 39 40
Non-splenectomized
150 100 50 0
1
2
3
4
5
6
7
8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Study Week Placebo* Romiplostim*
21 21 21 21 21 21 21 20 18 19 19 19 18 18 18 18 18 18 18 18 18 18 17 16 17 41 41 41 41 41 41 40 41 41 40 40 37 40 38 40 38 39 39 38 39 38 36 38 39 39
*Number available for measurement Kuter et al. Lancet 2008;371:395–403
Patients with bleeding events 59% reduction Placebo (n=41)
40 35
Romiplostim (n=84)
34
Percentage
30
42% reduction
25 20
14
15
12
10
7
5 0
Grade ≥ 2 Severity grades according to MedDRA 9.0 definition
Lyons et al. ASH 2007; poster
Grade ≥ 3
Reduction in immunoglobulin use Cumulative probability of immunoglobulin use during the 24-week treatment period
1.0
Cumulative Probability of Immunoglobulin Treatment
0.9 0.8
Hazard ratio (95% CI) 5.3 (2.6, 11.1), p < 0.001
0.7
Placebo Romiplostim
0.6 0.5 0.4 0.3 0.2 0.1 0.0 0
Patients at risk Placebo Romiplostim
2
4
6
8
10
12
14
16
18
20
22
24
Week 42 83
32 81
22 76
Cumulative probability of immunoglobulin use in 24 weeks 0.51 (SE: 0.08) for placebo; 0.13 (SE: 0.04) for romiplostim
Pullarkat et al. ASH 2007; poster
20 71
11 45
NICE Guidance (TA 221) on Romiplostim April 2011 1.1 Recommended for the treatment of adults with chronic ITP: – whose condition is refractory to standard active treatments and rescue therapies or – who have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and – if the manufacturer makes romiplostim available within the discount agreed as part of the patient access scheme 1.2 Only a haematologist should start and supervise treatment with romiplostim
Thrombopoietin-like agents Potential Adverse events • • • • • • • • •
headache, nausea, vomiting, fatigue, arthralgia thrombocytosis thrombosis – venous or arterial (risk factor) rebound thrombocytopenia on cessation hepatotoxicity (Eltrombopag) increased bone marrow fibrosis (reticulin/collagen) autoantibody formation reduced threshold for platelet activation risk of stimulating tumour/leukaemia growth
TPO agonist limitations • delayed onset action • continuous administration – ? intermittent
• unknown long term effects • cost • pregnancy
Approximate costs per course/mnth IvIg newly diagnosed acute & ‘rescue’ or pre procedure 400mg/kg x 5 £5000 or 1g/kg x 2
year
?
Rituximab persistent & chronic 375 mg/m2 x 4 £1000 100mg x 4 £6000
£1000 £6000
TPO receptor agonists prersistent & chronic Romiplostim £1700-£3400 Eltrombopag (50mg) £2000
£20,000-£40,000 £24000
Management of symptomatic ITP splenectomy
1st line
steroids - low dose
splenectomy
Steroids
other immune suppression
Rituximab
IvIg
IvIg
Long term
2nd line
splenectomy
steroids low dose
Rituximab
other immune suppression
??TPO agonists
TPO agonists On demand IvIg Steroids
TPO agonist
Total Grams Infused for ITP
60000
NICE recommended romiplostim for the treatment of patients with severe, chronic ITP on 27/04/2011
grams of immunoglobulin
50000
40000
30000
?
20000
10000
0 Q1 2010
Q2 2010
Q3 2010
Q4 2010
ITP
Q1 2011
Q2 2011
Second edition update
Clarification: Immune thrombocytopenia Immune thrombocytopenia (newly diagnosed) Immune thrombocytopenia (persistent) Immune thrombocytopenia (chronic – on demand)* Immune thrombocytopenia (chronic)
* For bleeding, trauma or pre-procedure
Clarification: Immune thrombocytopenia Database update will reflect intended advice and updated terminology for immune thrombocytopenia
Thank you
View more...
Comments